4D Molecular Therapeutics, Inc.

FDMT

US35104E1001

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
26.25 ^USD	-0.38%		-8.70%	+29.57%

Apr. 15	Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	MT
Apr. 15	RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	MT

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 2500 Value Index

March 19, 2021 at 12:00 am EDT

Latest news about 4D Molecular Therapeutics, Inc.

Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	Apr. 15	MT
RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	Apr. 15	MT
Certain Restricted Stock Units of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain Stock Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain Warrants of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing	Apr. 04	MT
BMO Capital Cuts 4D Molecular Therapeutics' Price Target to $63 From $70, Keeps Outperform Rating	Apr. 01	MT
Jefferies Raises 4D Molecular Therapeutics' Price Target to $58 From $30, Maintains Buy Rating	Apr. 01	MT
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis	Mar. 28	MT
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis	Mar. 28	CI
Transcript : 4D Molecular Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM	Mar. 13
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium? 2024	Feb. 12	CI
4d Molecular Therapeutics Insider Sold Shares Worth $737,788, According to a Recent SEC Filing	Feb. 08	MT
4D Molecular Therapeutics Launches $250 Million Stock Offering	Feb. 05	MT
4D Molecular Therapeutics Shares Surge on Positive Data From Phase 2 Study of Wet AMD Drug Candidate	Feb. 05	MT
Top Midday Gainers	Feb. 05	MT
BMO Capital Adjusts 4D Molecular Therapeutics' Price Target to $70 From $50, Keeps Outperform Rating	Feb. 05	MT
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	Feb. 05	RE
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell	Feb. 05	MT
RBC Raises PT on 4D Molecular Therapeutics to $35 From $25, Keeps Outperform Rating, Speculative Risk	Feb. 05	MT
Transcript : 4D Molecular Therapeutics, Inc. - Special Call	Feb. 05
Top Premarket Gainers	Feb. 05	MT
4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150	Feb. 03	CI

Chart 4D Molecular Therapeutics, Inc.

Duration

Period

More charts

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for 4D Molecular Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.25 USD

Average target price

54.22 USD

Spread / Average Target

+106.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
4D MOLECULAR THERAPEUTICS, INC.	+29.57%	1.34B
IQVIA HOLDINGS INC.	-0.10%	42.07B
LONZA GROUP AG	+50.98%	42.16B
MODERNA, INC.	+4.43%	39.77B
CELLTRION, INC.	-11.36%	26.68B
ICON PUBLIC LIMITED COMPANY	+5.67%	24.68B
ALNYLAM PHARMACEUTICALS, INC.	-22.84%	18.68B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.20%	12.11B
MEDPACE HOLDINGS, INC.	+26.30%	11.99B
UNITED THERAPEUTICS CORPORATION	+6.91%	11.06B

Other Biotechnology & Medical Research